Posted by Michael Wonder on 18 Apr 2023
Hugel hit with another complete response letter from the FDA
18 April 2023 - Hugel's much anticipated US launch of its botulinum toxin product, Letybo, has experienced yet another setback.
This is because the US FDA has issued a second complete response letter for the drug.
